CION Ameerpet
Hodgkin lymphoma is one of the most treatable and curable cancers, with a 5-year survival of roughly 80–90% across published series. This guide explains what the Hodgkins cure rate depends on and how CION's haematology team turns a diagnosis into a clear, hopeful plan.
If you or someone you love has just been diagnosed, here is the most important fact: Hodgkin lymphoma is one of the most treatable and curable of all cancers. Across large published patient series referenced in NCCN and ESMO guidance, the overall 5-year Hodgkin lymphoma survival rate sits at roughly 80–90%, and for people diagnosed at an early stage it is often higher still. For a cancer, those are genuinely reassuring numbers.
A "survival rate" is simply the proportion of people with a given diagnosis who are still alive after a set period — usually five years. It describes groups of patients studied in the past; it is not a prediction for any one person, and treatment keeps improving. Your own outlook — and your personal Hodgkins cure rate — depends on details specific to you, which we explain below.
To understand the disease itself, start with Hodgkin lymphoma — what it is, explore the whole Lymphoma hub, or read how our team plans care on the Lymphoma Treatment in Hyderabad page.
Hodgkin lymphoma is routinely described as one of the most curable cancers, with published series showing roughly 80–90% 5-year survival — and even higher in early-stage disease. By contrast, an aggressive non-Hodgkin type such as diffuse large B-cell lymphoma sits closer to 60–70%. These are group figures that vary by individual. (Source: outcomes summarised in NCCN and ESMO lymphoma clinical practice guidelines.)
No single number fits every patient. Doctors weigh several prognostic factors together — the same ones set out in NCCN and ESMO guidance — to estimate the outlook and shape the plan.
How far the lymphoma has spread is the strongest single factor. Early-stage disease (limited to one region) has excellent outcomes; even advanced-stage Hodgkin lymphoma has high cure rates with modern combination treatment.
Younger, otherwise-healthy patients tend to tolerate treatment well and respond strongly — one reason young adults with Hodgkin lymphoma often have some of the best outcomes.
The presence of "B symptoms" — unexplained fevers, drenching night sweats and weight loss — signals more active disease and is factored into staging and prognosis.
How quickly the lymphoma shrinks on a PET-CT scan done partway through treatment is a powerful modern prognostic marker. A strong early response is a very encouraging sign and can guide the rest of the plan.
Prognostic factors and outcomes vary by individual; this is a general guide, not a prediction. Your CION haematology team reviews all of these together before setting a plan.
We're never more than 30 minutes away. Same panel of specialists at every centre. Same tumour board reviews. Same NCCN protocols. Pick the closest one and call directly — or let us pick for you.
CION Ameerpet
CION Kukatpally
CION L.B. Nagar
CION Tolichowki
CION Masab Tank
CION Banjara Hills
CION Kompally
CION Balanagar
CION Siddipet
CION Sangareddy
Not sure which centre fits best? Tell us where you are — we'll suggest the closest one with the right specialists.
Help me pick the right centreTravelling for treatment? We may have a centre right where you are.
Don't see your city? Call 18002028726 — we'll find your nearest CION partner centre.
Trained at AIIMS, Tata Memorial, and leading international centres. Combined 150+ years of experience. Every complex case is reviewed by 3+ of them — together.
MBBS(Gold Medal), DNB(General Medicine), DM(Medical Oncology)(Gold Medal)
MBBS, MD(General Medicine), DM(Medical Oncology)(Adyar,Chennai), ECMO, MRCP SCE(UK)
MBBS, MD (General Medicine), DrNB (Medical Oncology), ECMO, MRCP SCE (Medical Oncology) (UK)
MBBS (AIIMS), MS (Surgery) (AIIMS), DNB (Surgical Oncology), MRCS (Edinburgh)
MBBS, MS(General Surgery), M.Ch(Surgical Oncology), FMAS, FARIS(Ongoing)
MBBS, MS (General Surgery), DrNB (Surgical Oncology), FALS Oncology
Want a specific doctor for your case? Mention them when booking.
Book Free ConsultationShare your name and number — we'll call you back within 30 minutes to schedule your consultation.
Just received a diagnosis, want to understand what your stage and prognosis mean, or need a second opinion before treatment? CION's haematology team is here to help.
It helps to see Hodgkin lymphoma survival alongside other lymphomas. The figures below are approximate 5-year survival ranges drawn from large published series and summarised in NCCN and ESMO guidance. They describe groups of patients studied in the past and vary considerably by individual — your stage, age and treatment response matter far more than any headline number.
| Lymphoma type | Approx. 5-year survival* | General behaviour |
|---|---|---|
| Hodgkin lymphoma (overall) | ~80–90% | Highly treatable; often curable, especially early-stage |
| Hodgkin lymphoma (early-stage) | Often >90% | Excellent outcomes with combination treatment |
| Nodular lymphocyte-predominant HL | Very favourable | Slow-growing; particularly good long-term outlook |
| Diffuse large B-cell lymphoma (an aggressive NHL) | ~60–70% | Aggressive but often curable with treatment |
*Approximate ranges from published series, summarised in NCCN and ESMO lymphoma guidelines. Figures vary by individual and are not a prediction for any one person. HL = Hodgkin lymphoma; NHL = non-Hodgkin lymphoma. For subtype detail see classical Hodgkin lymphoma and nodular lymphocyte-predominant Hodgkin lymphoma.
Good survival figures are earned by getting the details right — an accurate diagnosis, correct staging, the right intensity of treatment, and careful monitoring of the response. Here is how CION supports the best possible outcome, with every case reviewed by a multidisciplinary tumour board before the plan is set.
The subtype is confirmed on a biopsy by a pathologist, and a PET-CT defines the stage. Getting these right is the foundation of a good outcome and of any meaningful survival estimate. It also separates Hodgkin lymphoma from the many non-Hodgkin types, which are treated differently.
CION delivers combination chemotherapy and, where indicated, precision radiation therapy (IMRT/IGRT) in-house. Response is tracked with an interim PET-CT, allowing the team to confirm the disease is melting away as expected — a key driver of the high cure rate.
Even relapsed Hodgkin lymphoma is very treatable. It is managed with a different, more intensive drug approach — and for selected patients a stem-cell transplant, which CION coordinates through accredited partner facilities rather than delivering in-house. Newer antibody and immune-based treatments have further improved outcomes here.
Because so many people are cured, survivorship matters. CION provides long-term follow-up to watch for late effects and support recovery, and can explain what remission means for you.
Survival numbers can feel frightening or falsely precise. A few things are worth holding onto:
The best way to understand your own outlook is a conversation with a specialist who has seen your reports. CION offers a dedicated, free written second-opinion service, with transparent costs explained up front. Request your free second opinion or call 18002028726. You can also meet the best lymphoma doctors in Hyderabad and learn about the best lymphoma hospital in Hyderabad.
Get a free written second opinion from CION's haematology tumour board — we'll explain what your stage, subtype and treatment response mean for your prognosis.
These aren't paid endorsements or written reviews. These are video testimonials from real patients and families — recorded on their own phones, in their own words. Pick any one. Watch it. Then decide.
Read all 800+ reviews on Google
Start Your Story. Book Free Consultation.Hodgkin lymphoma is one of the most treatable cancers. Across published series, the overall 5-year survival rate is roughly 80–90%, and for people diagnosed with early-stage disease it is often higher still. Outcomes are shaped by the stage at diagnosis, age, the presence of "B symptoms" (fevers, night sweats, weight loss), and how well the disease responds on the interim PET-CT. These figures come from large published cohorts referenced in NCCN and ESMO guidance and describe groups of patients, not any one person — your own outlook depends on your specific situation. To understand what these numbers mean for you, see Hodgkin lymphoma — what it is or book a free consultation.
For most people, yes — Hodgkin lymphoma is considered one of the most curable cancers, particularly when it is found at an early stage. Many patients treated with standard chemotherapy, sometimes combined with radiation (IMRT), go into long-term remission and are effectively cured. Even advanced-stage disease has high cure rates with modern combination treatment. No doctor can promise a cure for any individual, and outcomes vary, but the odds are genuinely favourable. What "remission" and "cure" mean in practice is explained on our what remission means page. Discuss your own case with our team via Lymphoma Treatment in Hyderabad.
The Hodgkins cure rate depends on several factors that doctors weigh together. Stage (how far the lymphoma has spread) is the most important; early-stage disease has excellent outcomes. Other factors include your age, whether you have B symptoms, how many lymph-node areas are involved, blood-test findings, and — increasingly — how quickly the disease responds on the interim PET-CT scan done partway through treatment. A strong early response is a very good sign. These prognostic factors are set out in NCCN and ESMO guidelines. Your CION haematology team reviews all of them together before setting a plan.
Hodgkin lymphoma prognosis is, on average, more favourable than for many non-Hodgkin lymphomas, though non-Hodgkin lymphoma is a large and varied group. As a rough guide from published series, Hodgkin lymphoma carries a 5-year survival of about 80–90%, while an aggressive non-Hodgkin type such as diffuse large B-cell lymphoma sits closer to 60–70%; some slow-growing non-Hodgkin lymphomas are very indolent but harder to "cure" outright. These are group figures and vary by individual. Because the two behave differently, an accurate diagnosis by biopsy is essential — it directs the whole plan. Learn how they differ on our Hodgkin lymphoma page.
Yes, to a degree. Most Hodgkin lymphoma is classical Hodgkin lymphoma, which includes the common nodular sclerosis subtype and generally responds very well to standard treatment. A less common form, nodular lymphocyte-predominant Hodgkin lymphoma, tends to be slow-growing and carries a particularly good long-term outlook. Subtype matters, but stage, age and early treatment response usually influence prognosis more than subtype alone. The definitive subtype is confirmed on biopsy by a pathologist and reviewed by CION's tumour board before treatment is planned.
Even if Hodgkin lymphoma relapses after first treatment, the outlook remains meaningfully positive — many people achieve a durable second remission. Relapsed disease is usually treated with a different, more intensive chemotherapy approach, and for suitable patients this may be followed by a stem-cell transplant, which CION coordinates through accredited partner facilities rather than delivering in-house. Newer antibody and immune-based treatments have further improved outcomes in this setting. Because relapse is very treatable, it is not the same as running out of options. Read more about the options on our relapsed Hodgkin lymphoma page, and see what remission means.
Hodgkin lymphoma often affects teenagers and young adults, and this group generally has some of the best outcomes — younger, otherwise-healthy patients tend to tolerate treatment well and respond strongly. Fertility preservation and long-term survivorship care are important parts of planning at this age. Hodgkin lymphoma can also, rarely, be diagnosed during pregnancy; with careful, coordinated timing of treatment, outcomes for both mother and baby are usually good. These situations need an experienced team. See Hodgkin lymphoma in young adults and Hodgkin lymphoma and pregnancy for detail.
Browse our complete guide to lymphoma — symptoms, diagnosis, Hodgkin and non-Hodgkin subtypes, treatment, genetics, prognosis, survivorship and cost. Tap any topic to read more.